Drugs for HIV/AIDS, other diseases should be made more affordable, accessible, advocates say at intellectual property rights conference

Drugs for HIV/AIDS and other disease should be affordable and accessible to all people who need them, advocates from 15 countries who met recently in New Delhi to examine issues surrounding intellectual property rights said, the Hindustan Times reports.

Representatives from civil society groups in Brazil, China, Kenya, Malaysia, South Africa, Thailand and other countries shared their experiences in ensuring that patents do not hinder public health efforts, according to the Times. "The obstacles posed by global patent protection under" the World Trade Organization's Agreement on Trade-Related Aspects of International Property Rights present a "grave threat to public health and needs a global response," Anand Grover, project director of the HIV/AIDS unit at the India-based Lawyers Collective, said. He added, "Countries can learn from each other and help make medicines cheaper and easily available in the developing world."

According to Thai advocate Kannikar Kijtiwatchakul, the country's decision to issue compulsory licenses for antiretroviral and other drugs has "given new hope to thousands of Thai citizens who could not otherwise have access to these drugs." Some advocates also said that because India is the largest supplier of generic drugs to developing nations, the country should spearhead efforts worldwide to make drugs more affordable at a May meeting of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (Sharma, Hindustan Times, 4/22).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder